EGFR and lung carcinoma: As shown in Supplementary Figure S4, the impact of the VS-6063/JQ1 combination on cell viability appeared equal to that of VS-6063 with Cisplatin, an anti-NSCLC chemotherapeutic agent for treating lung cancer or Osimertinib, a third generation of EGFR inhibitor.